NCT04701983: An ongoing trial by Sanofi
This trial is ongoing. It must report results 3 months, 3 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT04701983 |
|---|---|
| Title | Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 16, 2020 |
| Completion date | April 11, 2025 |
| Required reporting date | April 11, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |